WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira).
The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions.
ad goes here:advert-1
SCROLL TO CONTINUE
Amjevita is the fourth biosimilar to be approved by the FDA. Last month, it approved Novartis AG’s biosimilar version of Amgen’s arthritis drug, etanercept (Enbrel).